reports
Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Break...
Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual Meeting last week. TLC599 is an investigational therapy developed by TLC BioSciences for osteoarthritis knee pain. In his late-breaking oral presentation, Prof. Hunter provided background on osteoarthritis...
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Sessi...
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) -- (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Selection Committee of the American College of Rheumatology (ACR) has accepted TLC's late-breaking abstract on TLC599 for oral presentation at ACR Con...
TLC Announces TLC599 Agreement with Endo
TLC Announces TLC599 Agreement with Endo One of the largest deals seen in Taiwan’s biotech sector SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with (Nasdaq: ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the ...
TLC BioSciences Announces Publication of TLC599 Phase II Results in Ar...
TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication use SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have...
TLC Announces Voluntary Delisting and Deregistration of American Depos...
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from th...
TLC Reports Second Quarter 2021 Financial Results and Provides Busines...
TLC Reports Second Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- , a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “The second quarter of 2021 was marked mainly by the timely approval of our liposomal amphotericin B product in India and the immediate partnerships for their commercialization and sales in the territor...
TLC Announces Details of Stock Swap Transactions
TLC Announces Details of Stock Swap Transactions TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the company’s board-approved stock swap transactions with Woods Investment Company, Ltd. (“Woods”) at a press conference held at 4:00pm Taipei time at the Taipei Exchange (TPEx). Details of the stock swap transactions are as follows: In response to the company's long-term development plan and realization ...
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of group (Zydus) (NSE: CADILAHC), an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC...
TLC Announces Approval of New Drug Application of Liposomal Amphoteric...
TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Central Drugs Standard Control Organization (CDSCO) of India has approved the New Drug Application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad® in Taiwan and AmphoTLC™ in India) for immediate importation per approved usage and in...
InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable...
InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the 23rd International Society for Aerosols in Medicine (ISAM) Congress. Pharmacokinetic studies on inhalable liposomal GS-441524 ...
TLC Reports First Quarter 2021 Financial Results and Provides Busines...
TLC Reports First Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. “The first quarter of 2021 is marked by continual progress in our lead programs, TLC599 and TLC590, as well as the global commercialization of Ampholipad, for which we look...
TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Yea...
TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years Running Praised as benchmark for small and medium-sized enterprises SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 03, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it once again ranks in the Top 5% in Corporate Governance Evaluation amongst all Taiwan Stock Exchange Corporation (TWSE) and Taipei Exchange (TPEx) listed companies. This marks the seventh consecutive y...
InspirMed to Present at the 23rd International Society for Aerosols in...
InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of (Nasdaq: TLC, TWO: 4152) that specializes in the development of inhalable liposome formulation programs, announced today that a late-breaking abstract describing the potential advantages of ISPM21 and ISPM19 has been accepted by the scientific committee for poster presentation at the 23rd International Society for Aerosols in Medicine (ISAM) Congress. The poster, titled “A Strate...
TLC to Present at Upcoming Virtual Investor Conferences
TLC to Present at Upcoming Virtual Investor Conferences SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company’s management team will be presenting at the following virtual investor conferences: HC Wainwright & Co Global Life Sciences Conference (March 9-10, 2021)Presentation: on-demand starting 7am ET, Tuesday, March 9, 2021 Oppenheimer 31st Annual Healthcare Conference (March ...
TLC Reports Fiscal Year End 2020 Financial Results and Provides Busine...
TLC Reports Fiscal Year End 2020 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the fiscal year ended December 31, 2020 and provided a business update. “In the tumultuous year that was 2020, we were fortunate enough to have achieved early patient enrollment in the Phase II clinical trial of our postsurgical pain program befor...
TLC Announces Completion of US$15 Million Financing for Subsidiary Ins...
TLC Announces Completion of US$15 Million Financing for Subsidiary InspirMed Inc. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 04, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that its subsidiary, InspirMed Inc., has completed a round of financing, raising US$15 million in cash from strategic investors in exchange for subsidiary equity. InspirMed is a newly established subsidiary of TLC specializing in the development of inhalable liposome...
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 fo...
TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis Pain On-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 28, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that patient enrollment of EXCELLENCE, the Phase III pivotal clinical trial for in patients with osteoarthritis (OA)...
TLC Provides Corporate Update at Investor Conference
TLC Provides Corporate Update at Investor Conference Patient enrollment of EXCELLENCE pivotal trial reaches 98% SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 18, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, held a virtual investor conference earlier today under the invitation of KGI Securities, and provided an update on the company’s pipeline as well as corporate strategy for the year ahead. George Yeh, President of TLC, commenced the conference and wel...
TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Cli...
TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal Technology can be quickly translated and applied to other drugs for direct, extended release delivery to the lungs and is open for collaboration SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 03, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the manuscript describing how inhalable liposomal hydroxychloroquine () may provide clin...
TLC Reports Third Quarter 2020 Financial Results and Provides Business...
TLC Reports Third Quarter 2020 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the third quarter ending September 30, 2020, and provided a business update. “As we journey toward the end of 2020, we are excited about the imminent enrollment completion in our EXCELLENCE trial of TLC599 for osteoarthritis pain,” commented George ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.